Publications by authors named "Yasir Al-Rawi"

Claim this Profile
R
Recognising, understanding and managing high conflict behaviours in healthcare.
James Kelly, Yasir Al-Rawi

Postgrad Med J· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
When Tithonus met corona: the COVID-19 pandemic and acute illness in the elderly.
Yasir Al-Rawi

BMJ Support Palliat Care· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Middle East-North Africa region: a cocoon for clinical trials.
Ghada Al Tajir, Yasir Al-Rawi

Account Res· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Refinement of the magnetic resonance diffusion-perfusion mismatch concept for thrombolytic patient selection: insights from the desmoteplase in acute stroke trials.
Steven Warach, Yasir Al-Rawi, Anthony J Furlan, Jochen B Fiebach, Max Wintermark

Stroke· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular occlusion enables selecting acute ischemic stroke patients for treatment with desmoteplase.
Jochen B Fiebach, Yasir Al-Rawi, Max Wintermark, Anthony J Furlan, Howard A Rowley

Stroke· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Desmoteplase in acute massive pulmonary thromboembolism.
Ulrich Tebbe, Peter Bramlage, Andreas Graf, Peter Lechleitner, Christoph Bode, Yasir Al-Rawi

Thromb Haemost· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study.
Werner Hacke, Anthony J Furlan, Yasir Al-Rawi, Antoni Davalos, Jochen B Fiebach

Lancet Neurol· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset.
Anthony J Furlan, Dirk Eyding, Gregory W Albers, Yasir Al-Rawi, Kennedy R Lees

Stroke· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.
Werner Hacke, Greg Albers, Yasir Al-Rawi, Julien Bogousslavsky, Antonio Davalos

Stroke· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis